SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Zai Lab Reports 40% Confirmed Response Rate in Previously Treated epNEC

Updated Phase 1b/2 data showed zocilurtatug pelitecan produced a confirmed 40.0% objective response rate.

ZLAB

Related stories